eCase: TD Progression

CE / CME

eCase: Managing Tardive Dyskinesia From Onset to Progression

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit 

Social Workers: 1.00 ASWB ACE CE Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Psychologists: 1.00 APA CE Credit

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: November 29, 2022

Expiration: November 28, 2023

Sneha Mantri
Sneha Mantri, MD, MS

Activity

Progress
1
Course Completed
In which of the following patient populations does TD appear to have the greatest impact on health-related quality of life?
Which of the following describes the mechanism of action of VMAT2 inhibitors?
Patients receiving which nonantipsychotic medication may be at risk of developing TD?

References

  1. Chen CY, Chiang HL, Fuh JL. Tardive syndrome: an update and mini-review from the perspective of phenomenology. J Chin Med Assoc. 2020;83:1059-1065.
  2. Carbon M, Hsieh CH, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78:e264-e278.
  3. Wijemanne S, Jankovic J, Evans RW. Movement disorders from the use of metoclopramide and other antiemetics in the treatment of migraine. Headache. 2016;56:153-161.
  4. Revet A, Montastruc F, Roussin A, et al. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry. 2020;20:308.
  5. Citrome L, Isaacson SH, Larson D, et al. Tardive Dyskinesia in Older Persons Taking Antipsychotics. Neuropsychiatr Dis Treat. 2021;17:3127-3134.
  6. McEvoy J, Gandhi SK, Rizio AA, et al. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual Life Res. 2019;28:3303-3312.
  7. Ayyagari R, Goldschmidt D, Mu F, et al. An experimental study to assess the professional and social consequences of tardive dyskinesia. Clin Psychopharmacol Neurosci. 2022;20:154-166.
  8. Farrar M, Lundt L, Franey E, et al. Patient perspective of tardive dyskinesia: results from a social media listening study. BMC Psychiatry. 2021;21:94.
  9. Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry. 2019;64:388-399.
  10. Kane JM, Correll CU, Nierenberg AA, et al. Revisiting the abnormal involuntary movement scale: proceedings from the Tardive Dyskinesia Assessment Workshop. J Clin Psychiatry. 2018;79:17cs11959.
  11. Lithium prescribing information. Eatontown, NJ: West-Ward; 2018
  12. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry. 2020;177:868-872.
  13. Niemann N, Jankovic J. Treatment of tardive dyskinesia: a general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs. 2018;78:525-541.
  14. Stahl SM. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? CNS Spectrums. 2018;23:239-247.
  15. Valbenazine prescribing information. San Diego, CA: Neurocrine Biosciences; 2017.
  16. Deutetrabenazine prescribing information. North Wales, PA: Teva; 2017.
  17. Aggarwal S, Serbin M, Yonan C. Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia. J Comp Eff Res. 2019;8:1077-1088.
  18. American Parkinson Disease Association. What is DaTscan and should I get one? www.apdaparkinson.org/article/what-is-a-datscan-and-should-i-get-one/. Accessed October 11, 2022.
  19. Cedars Sinai. FDG-PET scan. www.cedars-sinai.org/programs/imaging-center/exams/nuclear-medicine/fdg-pet-scan.html. Accessed October 11, 2022.
  20. Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012;8:15-21.